Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVANASDAQ:KNSANASDAQ:KURAOTCMKTS:PHGUF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$18.61+0.3%$17.92$15.20▼$21.28$1.17B0.35634,692 shs546,033 shsKNSAKiniksa Pharmaceuticals$26.84+3.1%$22.51$17.38▼$28.56$1.95B0.07480,548 shs308,978 shsKURAKura Oncology$6.09+5.7%$6.54$5.41▼$23.48$527.24M0.51.17 million shs936,096 shsPHGUFPharming Group$0.91$0.90$0.75▼$0.99$612.69M0.8715,292 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva0.00%-0.85%+5.94%+1.98%+18.97%KNSAKiniksa Pharmaceuticals0.00%-5.64%+35.11%+33.11%+33.59%KURAKura Oncology0.00%-10.82%0.00%-34.36%-72.14%PHGUFPharming Group0.00%0.00%+1.44%+5.72%-4.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINVAInnoviva4.2404 of 5 stars3.50.00.04.22.82.51.9KNSAKiniksa Pharmaceuticals2.6522 of 5 stars3.51.00.00.03.23.30.6KURAKura Oncology4.3734 of 5 stars4.52.00.04.73.30.00.6PHGUFPharming GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 3.00Buy$55.00195.54% UpsideKNSAKiniksa Pharmaceuticals 3.00Buy$38.8044.56% UpsideKURAKura Oncology 2.92Moderate Buy$23.89292.26% UpsidePHGUFPharming Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHGUF, KNSA, INVA, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.004/29/2025KNSAKiniksa PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/29/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.004/28/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/16/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/8/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.003/13/2025KNSAKiniksa PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/6/2025KURAKura OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $14.003/4/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/27/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$369.84M3.15$3.60 per share5.17$10.66 per share1.75KNSAKiniksa Pharmaceuticals$481.17M4.05N/AN/A$6.23 per share4.31KURAKura Oncology$67.99M7.75N/AN/A$5.35 per share1.14PHGUFPharming Group$245.32M2.50$0.01 per share89.78$0.33 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$179.72M-$1.0126.9712.01N/A18.31%20.84%11.38%5/14/2025 (Estimated)KNSAKiniksa Pharmaceuticals$14.08M-$0.25N/A107.36N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)KURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%N/APHGUFPharming Group-$10.55M-$0.01N/A∞N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)Latest PHGUF, KNSA, INVA, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals$0.02$0.11+$0.09$0.11$128.35 million$137.79 million2/26/2025Q4 2024INVAInnovivaN/A$0.57N/A$0.26N/A$91.81 million2/26/2025Q4 2024KURAKura Oncology-$0.65-$0.22+$0.43-$0.22$57.96 million$53.88 million2/25/2025Q4 2024KNSAKiniksa Pharmaceuticals-$0.06-$0.12-$0.06-$0.12$123.42 million$122.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/APHGUFPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.381.791.64KNSAKiniksa PharmaceuticalsN/A3.242.95KURAKura Oncology0.0211.4711.47PHGUFPharming Group0.533.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%KNSAKiniksa Pharmaceuticals53.95%KURAKura OncologyN/APHGUFPharming GroupN/AInsider OwnershipCompanyInsider OwnershipINVAInnoviva2.25%KNSAKiniksa Pharmaceuticals54.57%KURAKura Oncology6.40%PHGUFPharming GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10062.68 million61.54 millionOptionableKNSAKiniksa Pharmaceuticals22072.64 million32.80 millionOptionableKURAKura Oncology13086.58 million73.49 millionOptionablePHGUFPharming Group382671.07 millionN/ANot OptionablePHGUF, KNSA, INVA, and KURA HeadlinesRecent News About These CompaniesPharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...May 9 at 8:04 AM | uk.finance.yahoo.comPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)April 25, 2025 | finance.yahoo.comPharming announces positive recommendation from NICE for JoenjaApril 24, 2025 | finance.yahoo.comPharming Group to report first quarter 2025 financial results on May 8April 24, 2025 | finance.yahoo.comPharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDSApril 23, 2025 | finanznachrichten.deNICE Recommends Pharming Group's Joenja for Activated Phosphoinositide 3-Kinase Delta SyndromeApril 23, 2025 | precisionmedicineonline.comPharming Group (OTCMKTS:PHGUF) Short Interest Down 30.8% in MarchApril 20, 2025 | marketbeat.comPharming Group announces the filing of its 2024 Annual Report and Form 20-FApril 3, 2025 | finance.yahoo.comPharming Group (PHAR) Receives a Buy from H.C. WainwrightMarch 21, 2025 | markets.businessinsider.comPharming price target raised to $39 from $30 at OppenheimerMarch 14, 2025 | markets.businessinsider.comPharming Group N.V.: Pharming Group reports on results of the 2025 Extraordinary General Meeting of ShareholdersMarch 4, 2025 | finanznachrichten.dePharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percentFebruary 20, 2025 | uk.finance.yahoo.comPharming Group to participate in February investor conferenceFebruary 10, 2025 | finance.yahoo.comPharming Group price target raised to EUR 2.15 from EUR 1.60 at RBC CapitalDecember 20, 2024 | markets.businessinsider.comPharming Group Strengthens Pipeline with Abliva AcquisitionDecember 16, 2024 | msn.comPharming Group N.V. (PHAR)November 23, 2024 | finance.yahoo.comPharming price target lowered to $30 from $31 at OppenheimerOctober 28, 2024 | markets.businessinsider.comPharming Group’s Strong Q3 and CEO TransitionOctober 24, 2024 | msn.comPharming Group reports third quarter 2024 financial results and provides business updateOctober 24, 2024 | markets.businessinsider.comWhere Pharming Stands With AnalystsOctober 15, 2024 | benzinga.comPharming Group to report third quarter 2024 financial results on October 24October 10, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGUF, KNSA, INVA, and KURA Company DescriptionsInnoviva NASDAQ:INVA$18.61 +0.05 (+0.27%) Closing price 04:00 PM EasternExtended Trading$18.59 -0.02 (-0.10%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Kiniksa Pharmaceuticals NASDAQ:KNSA$26.84 +0.81 (+3.11%) Closing price 04:00 PM EasternExtended Trading$27.19 +0.35 (+1.30%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Kura Oncology NASDAQ:KURA$6.09 +0.33 (+5.73%) Closing price 04:00 PM EasternExtended Trading$6.10 +0.00 (+0.08%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Pharming Group OTCMKTS:PHGUF$0.91 0.00 (0.00%) As of 05/9/2025Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
